Algernon Pharmaceuticals CEO Christopher Moreau said the company has announced that its subsidiary Algernon NeuroScience has dosed the first subject in the Phase 1 DMT clinical stroke study. Moreau told Proactive this dosing was in the Netherlands where the study is being conducted at the Centre for Human Drug Research in Leiden. The first part of the study will use a single-escalating dose design aimed at identifying a safe and tolerable dose that will not produce psychedelic effects.
Proactive Canada Financial News
Proactive Canada
Proactive Canada
+1 604-688-8158
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.04 |
| Daily Change: | -0.003 -7.32 |
| Daily Volume: | 344 |
| Market Cap: | US$1.040M |
July 16, 2024 April 01, 2024 January 11, 2024 | |
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE
DevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...
CLICK TO LEARN MORE
